Last updated: May 29, 2026
Mavyret (glecaprevir/pibrentasvir) Suppliers: API, Excipients, and Contract Manufacturing for AbbVie’s HCV Regimen
Executive summary: Mavyret (glecaprevir/pibrentasvir) is produced via a multi-tier supply chain typical of fixed-dose, combination direct-acting antiviral (DAA) tablets. The program is supplied by specialized API and formulation contract manufacturing for both active ingredients and the finished dosage form, under AbbVie’s global commercial and regulatory framework. Named supplier identification (legal entities, facility addresses, and named manufacturers) requires Orange Book/FDA listing linkage, inspectional history, and procurement disclosure; without those, a supplier list can’t be produced accurately.
What companies supply Mavyret’s APIs (glecaprevir and pibrentasvir)?
Answer: Mavyret contains two DAAs, glecaprevir and pibrentasvir. The API supply is handled by manufacturers capable of producing both compounds to GMP standards and supporting combination-tablet linkage.
Glecaprevir API supply: what supplier types exist?
- High-complexity small-molecule API makers with established chiral/route control and GMP release testing.
- Companies with strong impurity-control capability for poly-heterocycle DAAs.
- Likely single-source-to-multiple-source strategy across regions to support commercial scale.
Pibrentasvir API supply: what supplier types exist?
- GMP API producers with validated synthetic routes and impurity profiles matching finished-product specifications.
- Makers with scale capacity for tablet-formulation integration and stable supply of consistent polymorph/particle characteristics where relevant.
Which contract manufacturing organizations (CMOs) make Mavyret tablets?
Answer: The finished dosage form (fixed-dose combination tablets) is manufactured by tablet CMOs or internal AbbVie facilities equipped for compression, film-coating, and packaging under GMP.
Tablet CMO capabilities that matter for Mavyret
- Dose uniformity and blend homogeneity controls for two-actives tablets.
- Stability program support for multi-month/regional shelf-life targets.
- Packaging line control for blistering/bottling and serialization regimes.
How does AbbVie’s supply chain structure Mavyret procurement?
Answer: AbbVie typically manages Mavyret supply through a controlled vendor network that covers:
- API manufacture for glecaprevir and pibrentasvir.
- Drug product manufacture (tablet formulation, compression, coating).
- Primary and secondary packaging.
- Quality oversight aligned with GMP, regulatory filings, and change-control requirements.
What is the FDA regulatory path for identifying Mavyret manufacturing sites?
Answer: The most reliable supplier identification is derived from FDA listings tied to the approved product and NDA technical details, including manufacturing site data that may appear in FDA databases and label manufacturing sections.
Orange Book status: why it matters for suppliers
If Mavyret has Orange Book listings that specify application and patent details, those entries often help anchor the product and its legal manufacturing chain. However, Orange Book does not always enumerate all upstream API/CMO suppliers explicitly.
Where can Mavyret manufacturers be found in regulatory documentation?
Answer: For finished dosage suppliers and many manufacturing sites, the highest-signal sources are:
- US prescribing information “Manufactured for” and label manufacturing sections.
- FDA product listing and facility identifiers where shown.
- Inspectional and compliance records that name facilities involved in drug substance and drug product manufacture.
- Partner and licensing announcements that sometimes name production partners.
What suppliers support Mavyret in global markets (EU, UK, Canada)?
Answer: Global supply generally relies on regional drug product release and distribution networks plus corresponding GMP manufacturing sites.
EU/UK specifics
- EU manufacturing sites are often listed in marketing authorization documents with named manufacturers for:
- drug product release
- quality batch testing
- packaging
- UK relies on comparable GMP frameworks with site-level detail embedded in authorization packages and regulator records.
Canada specifics
- Canadian licensing documentation can identify drug product and importation manufacturing responsibilities, which can differ from US roles.
How many suppliers exist for Mavyret’s APIs and drug product?
Answer: For combination DAAs, supply networks typically use multiple approved sources over time to cover demand, regulatory coverage, and risk mitigation. The exact number of legally approved suppliers must be evidenced by facility listings tied to the product and its manufacturing approvals.
What generic entry risks exist for Mavyret based on supplier concentration?
Answer: Supplier concentration affects only part of the generic risk picture. For fixed-dose combination DAAs, generic entry depends on:
- Bioequivalence and formulation performance
- Patent and regulatory exclusivity and Orange Book barriers
- Availability of GMP-compliant API supply chain for both actives
- Ability to meet quality specs for combination tablets
Supplier diversification can reduce launch delays caused by API shortages, but it does not override patent or exclusivity constraints.
What patent or exclusivity constraints affect supply substitution?
Answer: For branded DAAs like Mavyret, supply substitutions by generics or authorized producers are constrained by:
- Composition-of-matter and process patents (API synthesis)
- Formulation patents (fixed-dose tablet composition and manufacture)
- Method-of-use patents and regulatory exclusivity periods
- Any FDA exclusivity and patent listing/Paragraph IV challenges
Key Takeaways
- Mavyret’s supply chain is built around two APIs (glecaprevir, pibrentasvir) and a fixed-dose drug product manufacturing step (tablet).
- The supplier roster (named legal entities and facilities) can’t be stated accurately without direct linkage to FDA labeling/manufacturing sections and FDA/Orange Book/approval documentation that names the actual sites.
- For high-confidence due diligence, supplier identification must be anchored to facility-level regulatory listings for drug substance and drug product, not general industry assumptions.
FAQs
1) Who manufactures the glecaprevir and pibrentasvir APIs for Mavyret?
The API suppliers are determined by FDA and regulatory facility listings tied to the approved product and manufacturing approvals; a verified list requires those named sources.
2) Which company makes Mavyret tablets (drug product) under GMP?
Drug product manufacturing is identified in the approved label’s manufacturing statement and regulatory facility listings.
3) Are there multiple approved API suppliers for glecaprevir and pibrentasvir?
Combination DAAs commonly use multi-source strategies, but the exact approved number must be confirmed from the product’s regulatory manufacturing site records.
4) Does the Orange Book list Mavyret manufacturing sites or only patents?
Orange Book primarily lists patents and exclusivity-related information; manufacturing sites may be reflected elsewhere in FDA labeling and facility documentation.
5) How can a generic supplier assess whether it can source both APIs to launch?
A generic’s feasibility depends on validated API sourcing that meets GMP specs for both actives, plus the ability to overcome patent and regulatory barriers.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- U.S. Food and Drug Administration. Drug Product Database (Drugs@FDA) and related product labeling. FDA.
